Who is the CEO of NICE Holdings?

According to the DART company overview, NICE Holdings' representative director is 신종철 (name as registered in Korean). The company was founded on 1986-09-11.

Where is NICE Holdings listed?

NICE Holdings trades on the Korea Exchange KOSPI market under the ticker 034310. Its fiscal year ends in December.

What were NICE Holdings' latest quarterly results?

In Q2 2026, NICE Holdings reported revenue of ₩802bn and operating profit of ₩74.9bn. Figures come from reports filed on DART.

Does NICE Holdings pay a dividend?

Yes. For fiscal 2025, NICE Holdings paid a cash dividend of ₩560 per common share, a 4.1% yield as stated in its annual report, with a payout ratio of 52.0%. The prior year's dividend was ₩500.

Does NICE Holdings have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Dividend grower (dividend per share raised three years in a row); M&A / stake deal (merger, spin-off or acquisition/sale of shares in another company (90 days)). These are factual flags, not investment advice.

Which companies are in the same industry as NICE Holdings?

Under the Korean Standard Industrial Classification recorded on DART, NICE Holdings is grouped with 10 other listed companies in professional services. The most covered in Korean news over the past 30 days are Sungchang Enterprise Holdings, Jeil Pharma Holdings and Inveni.

NICE Holdings KRX:034310KOSPI

NICE · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked7since Sep 11

In Q2 2026, NICE Holdings reported revenue of ₩802bn and operating profit of ₩74.9bn. NICE Holdings (NICE) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 23 with 4 articles.

Filing signals Dividend grower M&A / stake deal Share pledge Screener

NICE Holdings quarterly results consolidated, KRW

Quarter	Operating profit	Net income
Q2 2026	₩74.9bn margin 9.3%	−₩14.6bn
Q1 2026	₩42.4bn margin 5.4%	₩34.8bn
Q4 2025 derived	₩37.6bn	−₩2.5bn
Q3 2025	₩61.4bn	₩36.4bn
Q2 2025	₩68.5bn	₩27.4bn
Q1 2025	₩30.6bn	₩15.2bn
Q4 2024 derived	₩40.1bn	₩39.5bn
Q3 2024	₩48.4bn	₩11.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

NICE Holdings top stories 2 weeks, by number of outlets

1
NICE "자회사 나이스프라퍼티 주식 514억원에 추가취득"
2 outlets · 2 articlesFirst report Oct 23 16:53 연합뉴스경제
2
[공시] NICE 타법인주식및출자증권취득결정
1 outlets · 1 articlesFirst report Oct 23 16:59 스페셜타임스
3
NICE, 나이스프라퍼티 주식 513억8814만원 규모 취득 결정
1 outlets · 1 articlesFirst report Oct 23 17:11 디지털투데이

Latest NICE Holdings news Korean headlines

Oct 2317:11

NICE, 나이스프라퍼티 주식 513억8814만원 규모 취득 결정
디지털투데이
Oct 2316:59

[공시] NICE 타법인주식및출자증권취득결정
스페셜타임스
Oct 2316:53
NICE "자회사 나이스프라퍼티 주식 514억원에 추가취득"
연합뉴스경제
1 more on this story · 1 outlets
- NICE, 자회사 나이스프라퍼티 주식 추가 취득[공시]파이낸셜뉴스 · Oct 23 17:39
Oct 122:22

한·일 스테이블코인 결제 실증···DSRV·NICE·SBI 맞손
한스경제
Oct 109:28

DSRV·NICE·SBI, 스테이블코인으로 韓日 결제 잇는다
뉴시스경제
Sep 1905:49

엔허투, 영국 NICE 문턱 넘었다…HER2 저발현 유방암 NHS 급여
약사공론

Articles per day 2 weeks

423

Company profile

CEO: 신종철
Industry: Professional services
Founded: 1986-09-11
Fiscal year-end: December
Head office: 서울특별시 영등포구
Website: nice.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

NICE Holdings dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩560	4.1%	52.0%
FY2024	₩500	4.4%	36.8%
FY2023	₩451	3.4%	412.8%

Raised 3 years in a row

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

김원우51.86%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Professional services

All in industry

Company	Latest quarter op. profit	Articles 30d
Sungchang Enterprise Holdings	₩391m	5
Jeil Pharma Holdings	−₩9.9bn	4
Inveni	₩11.2bn	3
Soulbrain Holdings	₩31.9bn	2
Asia Holdings	₩36.4bn	1
Eusu Holdings	₩12.8bn	0
GC	₩6.6bn	0
Daesung Holdings	₩2.7bn	0

Compare NICE Holdings side by side with these companies

NICE Holdings DART filings

Oct 2316:48

Equity acquisition / disposal 타법인주식및출자증권취득결정
Contracts & investment
Sep 1117:34

Other 대표이사(대표집행임원)변경(안내공시)
Other
Sep 1115:44

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports

Mentioned alongside 2 weeks

No co-mentioned companies yet.

NICE Holdings FAQ

Who is the CEO of NICE Holdings?: According to the DART company overview, NICE Holdings' representative director is 신종철 (name as registered in Korean). The company was founded on 1986-09-11.
Where is NICE Holdings listed?: NICE Holdings trades on the Korea Exchange KOSPI market under the ticker 034310. Its fiscal year ends in December.
What were NICE Holdings' latest quarterly results?: In Q2 2026, NICE Holdings reported revenue of ₩802bn and operating profit of ₩74.9bn. Figures come from reports filed on DART.
Does NICE Holdings pay a dividend?: Yes. For fiscal 2025, NICE Holdings paid a cash dividend of ₩560 per common share, a 4.1% yield as stated in its annual report, with a payout ratio of 52.0%. The prior year's dividend was ₩500.
Does NICE Holdings have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Dividend grower (dividend per share raised three years in a row); M&A / stake deal (merger, spin-off or acquisition/sale of shares in another company (90 days)). These are factual flags, not investment advice.
Which companies are in the same industry as NICE Holdings?: Under the Korean Standard Industrial Classification recorded on DART, NICE Holdings is grouped with 10 other listed companies in professional services. The most covered in Korean news over the past 30 days are Sungchang Enterprise Holdings, Jeil Pharma Holdings and Inveni.